Department of Brain Health News
The UNLV Department of Brain Health will advance research, education, and practice to benefit brain health and the care and treatment of people with brain disorders across the life span. Our faculty specialize in several areas that range from basic and clinical research in neurodegenerative disease, neuropsychology, and occupational therapy.
Current Brain Health News
A collection of local, national, and international news stories highlighting the people and programs of UNLV.
Lou Ruvo Center for Brain Health neurologist Dr. Jeffrey Cummings joins UNLV to help launch new program that will be crucial for an aging state population.
Formerly called School of Allied Health Sciences, the renamed unit has also launched new department of brain health.
New research unveils the anterior cingulate cortex’s role in memory retrieval and potential implications for dementia treatment.
Dr. Charles Bernick, School of Community Health Alumnus of the Year, has gotten Nevada into the thick of the fight against Alzheimer's.
Neuroscientist Jefferson Kinney's work with Ruvo Center for Brain Health is improving patient care while expanding opportunities for UNLV student learning.
Brain Health In The News
China has approved its first homegrown Alzheimer’s treatment — a novel drug based on algae, and the first breakthrough since 2003 in a field that has frustrated scientists and drug companies for decades.
Shanghai Green Valley Pharmaceuticals (Green Valley) today announced that China's National Medical Products Administration (NMPA) has approved Oligomannate (GV-971) as new drug for the treatment of "mild to moderate Alzheimer's disease (AD) and improving cognitive function."
Shanghai Green Valley Pharmaceuticals (Green Valley) announced today that China's National Medical Products Administration ( ANPM ) has approved oligo manato (GV-971) as a new drug for treatment of "Alzheimer's disease (AD) from benign to moderate and to improve cognitive function".
Shanghai Green Valley Pharmaceuticals (Green Valley) today announced that China's National Medical Products Administration (NMPA) has approved Oligomannate (GV-971) as new drug for the treatment of "mild to moderate Alzheimer's disease (AD) and improving cognitive function."
Promising research is coming out of a new department at the University of Nevada, Las Vegas focused on brain health.
Dr. Jeffrey Cummings, a world-renowned Alzheimer's researcher and leader in clinical trials, has been named the recipient of the 2019 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery. The prize, awarded by the Alzheimer's Drug Discovery Foundation (ADDF), recognizes leading researchers developing treatments for Alzheimer's disease and related dementias.
